Cardiac-directed parvalbumin transgene expression in mice shows marked heart rate dependence of delayed Ca2+ buffering action

Physiological Genomics

Volumn 33, Issue 3, 2008, Pages 312-322

  Day, Sharlene M ^a   Coutu, Pierre ^b   Wang, Wang ^b   Herron, Todd ^b   Turner, Immanuel ^b   Shillingford, Michael ^b   LaCross, Nathan C ^b   Converso, Kimber L ^b   Piao, Lin ^b   Li, Jingdong ^b   Lopatin, Anatoli N ^b   Metzger, Joseph M ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Diastole; Heart failure; Relaxation

Indexed keywords

CALCIUM ION; MAGNESIUM ION; PARVALBUMIN; BUFFER; CALCIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CALCIUM HOMEOSTASIS; CONTROLLED STUDY; GENE EXPRESSION; HEART FAILURE; HEART MUSCLE RELAXATION; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; TRANSGENE; TRANSGENIC MOUSE; ANIMAL; ANTIBODY SPECIFICITY; BIOLOGICAL MODEL; BIOSYNTHESIS; C57BL MOUSE; CALCIUM SIGNALING; GENETICS; HEART CONTRACTION; HEART MUSCLE; HEART MUSCLE CELL; HEART PACING; HEART RATE; HOMEOSTASIS; METABOLISM; ORGAN CULTURE TECHNIQUE; PHYSIOLOGY; SARCOPLASMIC RETICULUM;

MUS;

ANIMALS; BUFFERS; CALCIUM; CALCIUM SIGNALING; CARDIAC PACING, ARTIFICIAL; GENE EXPRESSION; HEART RATE; HOMEOSTASIS; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MODELS, CARDIOVASCULAR; MYOCARDIAL CONTRACTION; MYOCARDIUM; MYOCYTES, CARDIAC; ORGAN CULTURE TECHNIQUES; ORGAN SPECIFICITY; PARVALBUMINS; RATS; SARCOPLASMIC RETICULUM; TRANSGENES;

EID: 45549083673     PISSN: 10948341     EISSN: 15312267     Source Type: Journal    
DOI: 10.1152/physiolgenomics.00302.2007     Document Type: Article

References (52)

1. Bers DM. Cardiac excitation-contraction coupling. Nature 415: 198-205, 2002.
2. 2+-ATPase delays myocardial failure after myocardial infarction in rats at a cost of increased acute arrhythmias. Circulation 109: 1898-1903, 2004.
3. Coutu P, Bennett CN, Favre EG, Day SM, Metzger JM. Parvalbumin corrects slowed relaxation in adult cardiac myocytes expressing hypertrophic cardiomyopathy-linked alpha-tropomyosin mutations. Circ Res 94: 1235-1241, 2004.
4. Coutu P, Hirsch JC, Szatkowski ML, Metzger JM. Targeting diastolic dysfunction by genetic engineering of calcium handling proteins. Trends Cardiovasc Med 13: 63-67, 2003.
5. Coutu P, Metzger JM. Genetic manipulation of calcium-handling proteins in cardiac myocytes. 1. Experimental studies. Am J Physiol Heart Circ Physiol 288: H601-H612, 2005.
6. Coutu P, Metzger JM. Genetic manipulation of calcium-handling proteins in cardiac myocytes. II. Mathematical modeling studies. Am J Physiol Heart Circ Physiol 288: H613-H631, 2005.
7. Coutu P, Metzger JM. Optimal range for parvalbumin as relaxing agent in adult cardiac myocytes: gene transfer and mathematical modeling. Biophys J 82: 2565-2579, 2002.
8. Cross HR, Kranias EG, Murphy E, Steenbergen C. Ablation of PLB exacerbates ischemic injury to a lesser extent in female and male mice: protective role of NO. Am J Physiol Heart Circ Physiol 284: H683-H690, 2003.
9. Day SM, Westfall MV, Fomicheva EV, Hoyer K, Yasuda S, Cross NC, D'Alecy LG, Ingwall JS, Metzger JM. Histidine button engineered into cardiac troponin I protects the ischemic and failing heart. Nat Med 12: 181-189, 2006.
10. Del Monte F, Harding SE, Dec GW, Gwathmey JK, Hajjar RJ. Targeting phospholamban by gene transfer in human heart failure. Circulation 105: 904-907, 2002.
11. Del Monte F, Harding SE, Schmidt U, Matsui T, Kang ZB, Dec GW, Gwathmey JK, Rosenzweig A, Hajjar RJ. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation 100: 2308-2311, 1999.
12. Del Monte F, Lebeche D, Guerrero JL, Tsuji T, Doye AA, Gwathmey JK, Hajjar RJ. Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling. Proc Natl Acad Sci USA 101: 5622-5627, 2004.
13. 2+-ATPase in a rat model of heart failure. Circulation 104: 1424-1429, 2001.
14. Green HJ, Klug GA, Reichmann H, Seedorf U, Wiehrer W, Pette D. Exercise-induced fibre type transitions with regard to myosin, parvalbumin, and sarcoplasmic reticulum in muscles of the rat. Pflügers Arch 400: 432-438, 1984.
15. Haghighi K, Kolokathis F, Pater L, Lynch RA, Asahi M, Gramolini AO, Fan GC, Tsiapras D, Hahn HS, Adamopoulos S, Liggett SB, Dorn GW, MacLennan DH, Kremastinos DT, Kranias EG. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest 111: 869-876, 2003.
16. Hajjar RJ, Kang JX, Gwathmey JK, Rosenzweig A. Physiological effects of adenoviral gene transfer of sarcoplasmic reticulum calcium ATPase in isolated rat myocytes. Circulation 95: 423-429, 1997.
17. Hasenfuss G, Meyer M, Schillinger W, Preuss M, Pieske B, Just H. Calcium handling proteins in the failing human heart. Basic Res Cardiol 92, Suppl 1: 87-93, 1997.
18. He H, Giordano FJ, Hilal-Dandan R, Choi DJ, Rockman HA, McDonough PM, Bluhm WF, Meyer M, Sayen MR, Swanson E, Dillmann WH. Overexpression of the rat sarcoplasmic reticulum Ca2+ ATPase gene in the heart of transgenic mice accelerates calcium transients and cardiac relaxation. J Clin Invest 100: 380-389, 1997.
19. Herron TJ, Vandenboom R, Fomicheva E, Mundada L, Edwards T, Metzger JM. Calcium-independent negative inotropy by beta-myosin heavy chain gene transfer in cardiac myocytes. Circ Res 100: 1182-1190, 2007.
20. Hirsch JC, Borton AR, Albayya FP, Russell MW, Ohye RG, Metzger JM. Comparative analysis of parvalbumin and SERCA2a cardiac myocyte gene transfer in a large animal model of diastolic dysfunction. Am J Physiol Heart Circ Physiol 286: H2314-H2321, 2004.
21. Hoshijima M. Gene therapy targeted at calcium handling as an approach to the treatment of heart failure. Pharmacol Ther 105: 211-228, 2005.
22. Hoshijima M, Ikeda Y, Iwanaga Y, Minamisawa S, Date MO, Gu Y, Iwatate M, Li M, Wang L, Wilson JM, Wang Y, Ross J Jr, Chien KR. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med 8: 864-871, 2002.
23. 2+ dissociation rates from parvalbumin of frog muscle fibres. J Physiol 449: 399-410, 1992.
24. 2+ dissociation rates correlated with changes in relaxation rate of frog muscle fibres. J Physiol 441: 285-304, 1991.
25. Huq F, Lebeche D, Iyer V, Liao R, Hajjar RJ. Gene transfer of parvalbumin improves diastolic dysfunction in senescent myocytes. Circulation 109: 2780-2785, 2004.
26. Janczewski AM, Zahid M, Lemster BH, Frye CS, Gibson G, Higuchi Y, Kranias EG, Feldman AM, McTiernan CF. Phospholamban gene ablation improves calcium transients but not cardiac function in a heart failure model. Cardiovasc Res 62: 468-480, 2004.
27. Janssen PM, Stull LB, Marban E. Myofilament properties comprise the rate-limiting step for cardiac relaxation at body temperature in the rat. Am J Physiol Heart Circ Physiol 282: H499-H507, 2002.
28. 2+-specific regulatory sites of troponin C. J Biol Chem 269: 8919-8923, 1994.
29. Meyer M, Schillinger W, Pieske B, Holubarsch C, Heilmann C, Posival H, Kuwajima G, Mikoshiba K, Just H, Hasenfuss G. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation 92: 778-784, 1995.
30. Michele DE, Gomez CA, Hong KE, Westfall MV, Metzger JM. Cardiac dysfunction in hypertrophic cardiomyopathy mutant tropomyosin mice is transgene-dependent, hypertrophy-independent, and improved by beta-blockade. Circ Res 92: 255-262, 2002.
31. Miyamoto MI, Del MF, Schmidt U, DiSalvo TS, Kang ZB, Matsui T, Guerrero JL, Gwathmey JK, Rosenzweig A, Hajjar RJ. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci USA 97: 793-798, 2000.
32. 2+ in the heart: contraction versus intracellular signaling. J Clin Invest 116: 623-626, 2006.
33. Morgan JP. Abnormal intracellular modulation of calcium as a major cause of cardiac contractile dysfunction. N Engl J Med 325: 625-632, 1991.
34. Niederer SA, Hunter PJ, Smith NP. A quantitative analysis of cardiac myocyte relaxation: a simulation study. Biophys J 90: 1697-1722, 2006.
35. 2+-binding proteins parvalbumin and oncomodulin and their genes: new structural and functional findings. Biochim Biophys Acta 1306: 39-54, 1996.
36. Piacentino V III, Weber CR, Chen X, Weisser-Thomas J, Margulies KB, Bers DM, Houser SR. Cellular basis of abnormal calcium transients of failing human ventricular myocytes. Circ Res 92: 651-658, 2003.
37. Piao L, Li J, McLerie M, Lopatin AN. Cardiac IK1 underlies early action potential shortening during hypoxia in the mouse heart. J Mol Cell Cardiol 43: 27-38, 2007.
38. Rall JA. Role of parvalbumin in skeletal muscle relaxation. News Physiol Sci 11: 249-255, 1996.
39. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289: 194-202, 2003.
40. Rome LC. Design and function of superfast muscles: new insights into the physiology of skeletal muscle. Annu Rev Physiol 68: 193-221, 2006.
41. Schmidt AG, Edes I, Kranias EG. Phospholamban: a promising therapeutic target in heart failure? Cardiovasc Drugs Ther 15: 387-396, 2001.
42. Schmidt U, Zhu X, Lebeche D, Huq F, Guerrero JL, Hajjar RJ. In vivo gene transfer of parvalbumin improves diastolic function in aged rat hearts. Cardiovasc Res 66: 318-323, 2005.
43. Song Q, Schmidt AG, Hahn HS, Carr AN, Frank B, Pater L, Gerst M, Young K, Hoit BD, McConnell BK, Haghighi K, Seidman CE, Seidman JG, Dorn GW, Kranias EG. Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy. J Clin Invest 111: 859-867, 2003.
44. Szatkowski ML, Westfall MV, Gomez CA, Wahr PA, Michele DE, DelloRusso C, Turner II, Hong KE, Albayya F, Metzger JM. In vivo acceleration of heart relaxation performance by Parvalbumin gene delivery. J Clin Invest 107: 191-198, 2001.
45. 2+ uptake but decreases myocyte shortening. Circulation 110: 3553-3559, 2004.
46. Wahr PA, Michele DE, Metzger JM. Parvalbumin gene transfer corrects diastolic dysfunction in diseased cardiac myocytes. Proc Natl Acad Sci USA 96: 11982-11985, 1999.
47. Westfall MV, Rust EM, Metzger JM. Slow skeletal troponin I gene transfer, expression, and myofilament incorporation enhances adult cardiac myocyte contractile function. Proc Natl Acad Sci USA 94: 5444-5449, 1997.
48. 2+ signaling in cardiac myocyte excitation-transcription coupling. J Clin Invest 116: 675-682, 2006.
49. 2+ handling in heart failure. J Clin Invest 115: 556-564, 2005.
50. Yasuda S, Coutu P, Sadayappan S, Robbins J, Metzger JM. Cardiac transgenic and gene transfer strategies converge to support an important role for troponin I in regulating relaxation in cardiac myocytes. Circ Res 101: 377-386, 2007.
51. Zhao W, Frank KF, Chu G, Gerst MJ, Schmidt AG, Ji Y, Periasamy M, Kranias EG. Combined phospholamban ablation and SERCA1a overexpression result in a new hyperdynamic cardiac state. Cardiovasc Res 57: 71-81, 2003.
52. Zile MR, Baicu CF, Bonnema DD. Diastolic heart failure: definitions and terminology. Prog Cardiovasc Dis 47: 307-313, 2005.